Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?
The Motley Fool
by newsfeedback@fool.com (Prosper Junior Bakiny)February 16, 2026
Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/16/2026